Opendata, web and dolomites

DO->IT SIGNED

Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation (DO->IT)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DO->IT" data sheet

The following table provides information about the project.

Coordinator
LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE 

Organization address
address: Houghton Street 1
city: LONDON
postcode: WC2A 2AE
website: www.lse.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 7˙191˙755 €
 EC max contribution 3˙549˙833 € (49%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
 Code Call H2020-JTI-IMI2-2015-07-two-stage
 Funding Scheme /IMI2-CSA
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE UK (LONDON) coordinator 1˙263˙850.00
2    The Swedish Institute for Health Economics SE (LUND) participant 453˙440.00
3    SEMMELWEIS EGYETEM HU (BUDAPEST) participant 359˙918.00
4    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE UK (MANCHESTER) participant 298˙788.00
5    Technologie- und Methodenplattform für die vernetzte medizinische Forschung e. V. DE (BERLIN) participant 231˙190.00
6    FOLKEHELSEINSTITUTTET NO (OSLO) participant 186˙240.00
7    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 169˙776.00
8    TANDVARDS-OCH LAKEMEDELSFORMANSVERKET SE (STOCKHOLM) participant 149˙000.00
9    THE EUROPEAN MULTIPLE SCLEROSIS PLATFORM AISBL BE (BRUXELLES) participant 120˙745.00
10    UNIVERSITA COMMERCIALE LUIGI BOCCONI IT (MILANO) participant 119˙921.00
11    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 100˙644.00
12    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 96˙321.00
13    Amgen NV BE (Bruxelles) participant 0.00
14    Asociacion Nacional Empresarial de la Industria Farmacéutica ES (MADRID) participant 0.00
15    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
16    Boehriger Ingelheim International GmbH DE (INGELHEIM) participant 0.00
17    Celgene International II Sarl CH (BOUDRY) participant 0.00
18    Eli Lilly and Company Ltd UK (Basingstoke) participant 0.00
19    European Federation of Pharmaceutical Industries and Associations BE (BRUXELLES) participant 0.00
20    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
21    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
22    Health iQ LTD. UK (LONDON) participant 0.00
23    INSTITUT DE RECHERCHE INTERNATIONAL SERVIER FR (SURESNES) participant 0.00
24    InterSystems GmbH DE (DARMSTADT) participant 0.00
25    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
26    Merck KGaA DE (Darmstadt) participant 0.00
27    Merck Sharp and Dohme, Corp. US (WHITEHOUSE STATION NJ) participant 0.00
28    Norwegian Medicines Agency NO (OSLO) participant 0.00
29    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
30    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
31    Pfizer Ltd UK (SANDWICH) participant 0.00
32    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
33    The Association of the British Pharmaceutical Industry UK (LONDON) participant 0.00
34    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 0.00
35    UCB Biopharma SPRL BE (BRUSSELS) participant 0.00
36    Verband forschender Arzneimittelhersteller e.V. DE (Berlin) participant 0.00

Mappa

 Project objective

The overall goal of the Big Data for Better Outcomes (BD4BO) programme is to facilitate the use of ‘big data’ to promote the development of value-based, outcomes-focused healthcare systems in Europe. To fully exploit the transformative potential of big data, consideration will need to be taken of the use of detailed personal and biological information across the spectrum of care delivery, starting from the development of innovative medicines and treatments, to market access and adoption, diffusion, and use in healthcare systems by providers and patients. This paradigm shift requires shared understanding and standards among healthcare stakeholders including patients, providers, payers, regulators, policy makers, pharmaceutical industry, and academia.

OBJECTIVES The proposed Coordination and Support Action (CSA) will establish an enabling platform that brings together these stakeholder groups across the BD4BO programme to ensure quality and consistency of individual projects in line with the overarching programme objective. Our consortium therefore aims to promote the use of big Data for better Outcomes, policy Innovation and healthcare system Transformation (DO->IT). Accordingly, we will: • Define a programme strategy that ensures quality, consistency and sustainability of health outcomes related activities across individual BD4BO projects. • Integrate, synthesise, and manage knowledge from all BD4BO projects, making it easily accessible via a single knowledge exchange platform. • Act as pivotal point of collaboration, stakeholder engagement and communication for all BD4BO projects. • Provide transparency and enable the use of patient health data and human biological samples for research purposes by developing minimum data privacy standards for Informed Consent Forms (ICFs) and supporting materials for use by individual BD4BO disease-specific projects and more widely in the Research and Development (R&D) sector.

CONSORTIUM The multidisciplinary composition, uniting public and private sector stakeholders is the essential feature of the DO->IT consortium. The public membership spans world-leading expertise in health systems and policy, with specific expertise in the definition and use of validated outcomes from real world data sources. It comprises partners from large and small European countries as well as from pan-European and US organisations, disease-specialists from across the range of vertical programmes, including relevant patient organisations for existing and planned BD4BO projects, and representation from all relevant big data stakeholders, for example national decision makers, regulators, registries, healthcare providers, and researchers. The private consortium members include 22 pharmaceutical and biotechnology companies, national and pan-European pharma industry organisations, EFPIA Partners in Research with significant data management expertise including SMEs and organisations with a pan-European and global footprint. The public and private partners will also contribute their vast experience and networks to build on learnings and best practices of other real world evidence data or big data related IMI projects such as ADAPT-SMART, GetReal, EMIF, EHR4CR, OpenPHACTS and eTRIKS. In addition, DO->IT will leverage regular contact with its carefully selected International Advisory Board (IAB) and the Data Privacy and Ethics Committees (DPECs) to inform activities and maximise the impact of BD4BO outputs.

DO->IT will combine its full range of stakeholder knowledge with an holistic approach to address legal, ethical, methodological and practical issues in the collection, storage, and use of personal data across the medicinal product life-cycle.

WORK PLAN The work plan for the CSA is structured in four Work Packages (WPs). WP1 is concerned with the Programme Strategy and Coordination. It provides clear strategic guidance across individual projects within the BD4BO programme, ensuring common goals and s

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DO->IT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DO->IT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.)

eHealth Week (2016)

eHealth Week 2016

Read More  

EHW15 (2015)

High Level eHealth Conference 2015

Read More  

hPSCreg (2017)

Human Puripotent Stem Cell Registry

Read More